Fostemsavir resistance-associated polymorphisms in HIV-1 subtype C in a large cohort of treatment-naïve and treatment-experienced individuals in Botswana

Microbiol Spectr

The article “Ostemsavir Resistance-Associated Polymorphisms in HIV-1 Subtype C in a Large Cohort of Treatment-Naïve and Treatment-Experienced Individuals in Botswana” investigates genetic variations in the HIV-1 virus that may be associated with resistance to ostemsavir, a medication used in the treatment of HIV. The study focuses on individuals in Botswana, including both those who have never received HIV treatment (treatment-naïve) and those who have undergone treatment (treatment-experienced).

Ostemsavir is a type of antiretroviral drug, and understanding the prevalence of genetic variations linked to resistance is crucial for tailoring effective treatment plans. The study examines how commonly these variations occur in the HIV-1 subtype C, which is prevalent in Botswana.

The results of the study provide insights into the genetic landscape of HIV in Botswana, helping healthcare providers understand potential challenges in using ostemsavir for treatment in this specific population. This information aids in the development of more personalized and effective strategies for managing HIV, ensuring that medications are chosen based on the genetic characteristics of the virus prevalent in the region.

Disclaimer: This lay summary was generated by AI and has not been approved by any of the authors yet.

SANTHE is an Africa Health Research Institute (AHRI) flagship programme funded by the Science for Africa Foundation through the DELTAS Africa programme; the Bill & Melinda Gates Foundation; Gilead Sciences Inc.; and the Ragon Institute of Mass General, MIT, and Harvard.